It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth

Bibliographic Details
Main Authors: Megan M. Oberle, Aaron S. Kelly
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Endocrinology
Subjects:
GLP-1 receptor agonists
pedatrics
type 2 diabetes
obesity
weight management
adolescents
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2019.00738/full
id doaj-bc83f745d86240c38afc36cff566cdb1
record_format Article
spelling doaj-bc83f745d86240c38afc36cff566cdb12020-11-24T21:51:09ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922019-10-011010.3389/fendo.2019.00738488383It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in YouthMegan M. Oberle0Megan M. Oberle1Aaron S. Kelly2Aaron S. Kelly3Department of Pediatrics, University of Minnesota, Minneapolis, MN, United StatesCenter for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, MN, United StatesDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, United StatesCenter for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, MN, United Stateshttps://www.frontiersin.org/article/10.3389/fendo.2019.00738/fullGLP-1 receptor agonistspedatricstype 2 diabetesobesityweight managementadolescents
collection DOAJ
language English
format Article
sources DOAJ
author Megan M. Oberle
Megan M. Oberle
Aaron S. Kelly
Aaron S. Kelly
spellingShingle Megan M. Oberle
Megan M. Oberle
Aaron S. Kelly
Aaron S. Kelly
It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
Frontiers in Endocrinology
GLP-1 receptor agonists
pedatrics
type 2 diabetes
obesity
weight management
adolescents
author_facet Megan M. Oberle
Megan M. Oberle
Aaron S. Kelly
Aaron S. Kelly
author_sort Megan M. Oberle
title It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
title_short It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
title_full It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
title_fullStr It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
title_full_unstemmed It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
title_sort it is time to consider glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes in youth
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2019-10-01
topic GLP-1 receptor agonists
pedatrics
type 2 diabetes
obesity
weight management
adolescents
url https://www.frontiersin.org/article/10.3389/fendo.2019.00738/full
work_keys_str_mv AT meganmoberle itistimetoconsiderglucagonlikepeptide1receptoragonistsforthetreatmentoftype2diabetesinyouth
AT meganmoberle itistimetoconsiderglucagonlikepeptide1receptoragonistsforthetreatmentoftype2diabetesinyouth
AT aaronskelly itistimetoconsiderglucagonlikepeptide1receptoragonistsforthetreatmentoftype2diabetesinyouth
AT aaronskelly itistimetoconsiderglucagonlikepeptide1receptoragonistsforthetreatmentoftype2diabetesinyouth
_version_ 1725880067532259328

Similar Items